| Officer | Age | In this role | Joined | Pay | Source |
|---|---|---|---|---|---|
|
Mark White
Also a director
President, Chief Executive Officer and Director
|
65 | Not stated | Not stated | Not reported | |
|
David Owens
Also a director
Chief Medical Officer and Director
|
65 | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Joint venture formed with Wider to clinically develop, market, sell and distribute Gen-2 tACS devices in China and other countries in the region; Wider and Nexalin Technology own 52% and 48% of the Joint Venture.
Company issued 181,818 shares of common stock to Wider and its affiliates in satisfaction of obligations under their collaborative agreement and continuing research and development efforts.
Company received a distribution from the Joint Venture, which reduced its investment asset.
Five-year consulting agreement from 2018, extended and amended effective July 1, 2025, for corporate development, financing and international operations services, including a monthly cash fee and semi-annual stock awards.
Sub-lease of approximately 4,000 square feet of office space for the principal executive office, with the Company paying the primary landlord's rent costs directly.
Loading...
